Simple, direct, and informative method for the assessment of CYP2C19 enzyme inactivation kinetics

Drug Metabolism and Disposition

Volumn 39, Issue 3, 2011, Pages 412-418

  Salminen, Kaisa A ^a   Leppänen, Jukka ^a   Venäläinen, Jarkko I ^b   Pasanen, Markku ^a   Auriola, Seppo ^a   Juvonen, Risto O ^a   Raunio, Hannu ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; DIBENZYLFLUORESCEIN; FLUORESCEIN; FLUORESCEIN BENZYL ESTER; FLUORESCEIN BENZYL ETHER; FLUORESCENT DYE; ISONIAZID; TICLOPIDINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; FLUOROMETRY; IC 50; METABOLISM; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; BIOCATALYSIS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME ASSAYS; ENZYME INHIBITORS; FLUORESCEINS; FLUORESCENT DYES; HUMANS; HYDROGEN-ION CONCENTRATION; ISONIAZID; KINETICS; RECOMBINANT PROTEINS; SPECTROMETRY, FLUORESCENCE; TICLOPIDINE; TRANYLCYPROMINE;

EID: 79951897656     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036376     Document Type: Article

References (30)

1. Adamczyk M, Grote J, and Moore JA (1999) Chemoenzymatic synthesis of 3′-O-(carboxyalkyl)fluorescein labels. Bioconjug Chem 10:544-547.
2. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443-469.
3. Copeland RA (2005) Evaluation of Enzyme Inhibitors in Drug Discovery. a Guide for Medicinal Chemists and Pharmacologists, John Wiley & Sons, Inc., Hoboken, NJ.
4. Crespi CL, Miller VP, and Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188-190.
5. Crespi CL and Stresser DM (2000) Fluorometric screening for metabolism-based drug-drug interactions. J Pharmacol Toxicol Methods 44:325-331.
6. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, and Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23-29.
7. Donahue SR, Flockhart DA, Abernethy DR, and Ko JW (1997) Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther 62:572-577.
8. Fairman DA, Collins C, and Chapple S (2007) Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation? Drug Metab Dispos 35:2159-2165.
9. Fowler S and Zhang H (2008) In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J 10:410-424.
10. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2006) A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 7:315-334.
11. Grime KH, Bird J, Ferguson D, and Riley RJ (2009) Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 36:175-191.
12. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metab Dispos 37:1355-1370.
13. Hong Y, Cho M, Yuan YC, and Chen S (2008) Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromatase. Biochem Pharmacol 75:1161-1169.
14. Kalgutkar AS, Obach RS, and Maurer TS (2007) Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407-447.
15. 50 method and multiplexing high-performance liquid chromatography. J Pharm Sci 96:2485-2493.
16. Miller VP, Stresser D, Crespi CL, and Charles L (2001), inventors; Gentest Corp, assignee.The use of fluorescein aryl ethers in high throughput cytochrome P450 inhibition assays. World patent WO0114361 (A1). 2001 March 1.
17. Nishimura Y, Kurata N, Iwase M, and Yasuhara H (2003) Mechanism-based inactivation of human CYP1A2 and CYP2C19-mediated metabolism by isoniazid. Drug Metab Rev 35:50.
18. Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, and Ikeda T (2009) Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica 39:836-843.
19. Obach RS (2009) Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Devel 12:81-89.
20. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, and Raunio H (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667-715.
21. Polasek TM, Elliot DJ, Somogyi AA, Gillam EM, Lewis BC, and Miners JO (2006) An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol 61:570-584.
22. Polasek TM and Miners JO (2007) In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 3:321-329.
23. Richter T, Mürdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189-197.
24. Riley RJ, Grime K, and Weaver R (2007) Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3:51-66.
25. Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, and Kobayashi S (1999) Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol 47:454-457.
26. 12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 30:1964-1977.
27. Wen X, Wang JS, Neuvonen PJ, and Backman JT (2002) Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 57:799-804.
28. Venkatakrishnan K and Obach RS (2007) Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 8:449-462.
29. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.
30. Zhou ZW and Zhou SF (2009) Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Opin Drug Metab Toxicol 5:579-605.